Treatment of ob/ob mice with TTR-ASOs improves insulin sensitivity.

Slides:

Advertisements

Similar presentations

Philip J. Barter, et al. Circulation 2011;124:

Advertisements

Body weight and oral glucose tolerance in diet-induced obese rats at 5 weeks post-surgery. Body weight and oral glucose tolerance in diet-induced obese.

Nikole J. Byrne et al. BTS 2017;j.jacbts

Dandan Wang et al. BTS 2018;3: Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),

Improvement of insulin sensitivity by treatment of the annexin A1 receptor agonist in HFD mice. Improvement of insulin sensitivity by treatment of the.

Intra‐eWAT administration of FGF21 vectors in ob/ob mice

Treatment with AAV8‐hAAT‐FGF21 improves insulin sensitivity and glucose tolerance Treatment with AAV8‐hAAT‐FGF21 improves insulin sensitivity and glucose.

Blocking Ca2+ Channel β3 Subunit Reverses Diabetes

(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).

Urine ammonia is highly correlated with plasma K

Cyp8b1−/− mice have improved islet insulin secretion and increased islet insulin content but unchanged β-cell mass. Cyp8b1−/− mice have improved islet.

Overexpression of BTG2 resulted in an increase in hepatic gluconeogenesis. Overexpression of BTG2 resulted in an increase in hepatic gluconeogenesis. A:

Deletion of neuronal insulin receptor signaling reduces TG secretion, while the targeted knockout of insulin receptors restricted to the periphery increases.

Body weight, blood glucose, and iron status in STZ-induced type 1 diabetic rats with or without insulin therapy. Body weight, blood glucose, and iron status.

Glucose, insulin, and AGE levels during an OGC before and after RT

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

1018-NT-β-cell clusters protect mice from STZ-induced diabetes.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

GSIS. GSIS. In vivo: serum insulin levels at fasting state and 30 min after glucose injection (A) and the fold change in serum insulin after glucose loading.

Ion channels expression and insulin secretion in the pancreatic islets of male offspring. Ion channels expression and insulin secretion in the pancreatic.

Influence of insulin on AdipoR1 mRNA expression in murine C2C12 myotubes. Influence of insulin on AdipoR1 mRNA expression in murine C2C12 myotubes. Data.

A: The change of plasma glucose in opioid μ-receptor knockout diabetic mice and wild-type controls receiving an oral intake of metformin (100 mg/kg). A:

Glycemia and glucose tolerance of RIP-N mice.

Correlation of myotube AdipoR1 (A) and AdipoR2 (B) mRNA expression with insulin secretion (n = 40). Correlation of myotube AdipoR1 (A) and AdipoR2 (B)

PMPs survive STZ cytotoxicity and produce larger colonies with a higher yield of insulin+ progeny. PMPs survive STZ cytotoxicity and produce larger colonies.

Insulin secretion/insulin resistance (disposition) index (ΔINS/ΔGLU ÷ IR) in subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT),

Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different.

Appearance of insulin in plasma and CSF at different times after the administration of subcutaneous DET and GLAR in mice and the effect of chronic DET.

Plasma growth hormone concentrations during a 65-min infusion of acyl ghrelin at 0.3, 0.9, or 1.5 nmol/kg/h, or saline. Plasma growth hormone concentrations.

TXNIP and caspase-1 protein levels are increased in the adipose tissue of ob/ob mice. TXNIP and caspase-1 protein levels are increased in the adipose tissue.

Comparison of women carrying a male fetus and those carrying a female fetus, with respect to mean adjusted blood glucose levels during the OGTT (A), mean.

Measurement of insulin release from islets evoked by glucose, diazoxide, and high K+. Measurement of insulin release from islets evoked by glucose, diazoxide,

Glucose tolerance in WT and TRPM2-KO mice.

Effects of the β-cell–specific expression of mKL on blood glucose levels, glucose tolerance, insulin sensitivity, and plasma insulin levels in STZ-induced.

Insulin sensitivity in athletes and sedentary normal-weight and obese, young, and old individuals. Insulin sensitivity in athletes and sedentary normal-weight.

The effect of VSG on body weight and body fat in GLP-1r KO mice.

A: Chemical structure of pterosin A

GLP-1 and gastrin combination therapy increases pancreatic insulin content (A) and β-cell mass (B) in NOD mice. GLP-1 and gastrin combination therapy increases.

ATL-801 treatment increases insulin sensitivity in KKAY mice.

Treatment of ob/ob mice with TTR-ASOs reduces adipose tissue inflammation. Treatment of ob/ob mice with TTR-ASOs reduces adipose tissue inflammation. A:

Chop deletion preserves β-cell function in P58IPK−/− mice.

Arterial and portal plasma glucagon levels and the portal-arterial (P-A) glucagon gradient in the control period (−40 to 0 min) and after administration.

The portal-arterial (P-A) insulin gradient and arterial plasma c-peptide levels in the control period (−40 to 0 min) and after administration of the glycogen.

USP2–45 regulates hepatic gluconeogenesis.

Subchronic glycemic effects after vehicle, metformin, SGLT2I, or combination treatment. Subchronic glycemic effects after vehicle, metformin, SGLT2I, or.

Effect of anandamide on blood glucose clearance and insulin sensitivity. Effect of anandamide on blood glucose clearance and insulin sensitivity. A: Intraperitoneal.

Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.

Effect of cold exposure on determinants of glucose tolerance.

HFD feeding induced insulin resistance in TRIB3 MOE mice.

High-glucose–induced insulin resistance in TRIB3 MOE mice.

Food intake in response to central infusion of glucose (squares) or insulin (triangles) and in response to successive central infusion of insulin, insulin.

Insulin resistance and hepatic steatosis in ASKO mice.

Treatment of high-fat diet–fed mice with TTR-ASOs decreases circulating TTR and RBP4 levels, and improves insulin sensitivity. Treatment of high-fat diet–fed.

Effects of Rosi treatment on ASKO mice.

Effects of chow-diet feeding on control and TRIB3 MOE mice.

Effects of berberine on in vivo metabolism in two animal models of insulin resistance. Effects of berberine on in vivo metabolism in two animal models.

Metabolic effects of VSG in GLP-1r KO mice.

Glucose-stimulated insulin secretion, plasma glucagon levels, and pancreatic hormone contents. Glucose-stimulated insulin secretion, plasma glucagon levels,

GTTs and ITTs. A: GTTs of WT (◇), LepTg (♦), Akita (open circles), and LepTg:Akita (closed circles) mice at 8 and 16 weeks of age. GTTs and ITTs. A: GTTs.

Loss of Phb2 in β-cells induces development of diabetes over a 3-week period in β-Phb2−/− mice. Loss of Phb2 in β-cells induces development of diabetes.

Pioglitazone administration acutely inhibits insulin secretion and increases insulin clearance in Wistar rats. Pioglitazone administration acutely inhibits.

Deficiency of adipocyte IKKβ does not affect diet-induced weigh gain but results in an exaggerated diabetic phenotype when challenged with an HFD. A: IKKβ.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

A: Pharmacokinetic (plasma insulin concentration) response to administration of an oral insulin formulation (uninterrupted line) and subcutaneous regular.

Effects of d-xylose or sucralose (control) with or without sitagliptin on gastric emptying (half-emptying time [T50]) (n = 12). Effects of d-xylose or.

Fig. 1. The HCN channel blocker ivabradine (IVA) is analgesic in a mouse model of type 1 diabetes. The HCN channel blocker ivabradine (IVA) is analgesic.

Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.

Fig. 3. Effects of SFN in mice with diet-induced diabetes.

Presentation transcript:

Treatment of ob/ob mice with TTR-ASOs improves insulin sensitivity. Treatment of ob/ob mice with TTR-ASOs improves insulin sensitivity. A: Glucose and insulin levels 5 h after the removal of food in male lean and ob/ob mice at baseline (0 weeks), and after 2, 6, and 9 weeks of ASO treatment. ASO treatment was started at 7 weeks of age. *P < 0.05 vs. lean mice, #P < 0.05 vs. ob/ob mice treated with control ASO at the same time point by ANOVA. B: Correlation of plasma RBP4 levels with insulin and glucose × insulin product in male ob/ob mice after 2 weeks of TTR-ASO treatment. Glucose and insulin levels were measured 5 h after the removal of food. C: Insulin tolerance test (2.4 units/kg s.c.) after 4 weeks of ASO treatment. *P < 0.05 for ob/ob mice treated with TTR-ASO vs. ob/ob mice treated with saline solution or control ASO by ANOVA with repeated measures for the comparison of each curve. D: Glucose tolerance test (1 mg/kg s.c.) after 3 weeks of ASO treatment. +P < 0.05 for ob/ob mice treated with TTR-ASO vs. saline solution treatment, and P = 0.09 vs. control ASO treatment by ANOVA with repeated measures for comparison of each curve. n = 8 to 16 per group. Data are expressed as the mean ± SEM. AU, arbitrary units; Con ASO, control ASO treatment; Sal, saline solution treatment. Laura Zemany et al. Diabetes 2015;64:1603-1614 ©2015 by American Diabetes Association